



US007056906B2

(12) **United States Patent**
Strony

(10) **Patent No.:** **US 7,056,906 B2**
(45) **Date of Patent:** ***Jun. 6, 2006**

(54) **COMBINATIONS OF HORMONE REPLACEMENT THERAPY COMPOSITION(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR CONDITIONS IN POST-MENOPAUSAL WOMEN**

(75) Inventor: **John T. Strony**, Lebanon, NJ (US)

(73) Assignee: **Schering Corporation**, Kenilworth, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **10/247,085**

(22) Filed: **Sep. 19, 2002**

(65) **Prior Publication Data**

US 2003/0119796 A1 Jun. 26, 2003

Related U.S. Application Data

(63) Continuation-in-part of application No. 10/166,942, filed on Jun. 11, 2002.

(60) Provisional application No. 60/324,118, filed on Sep. 21, 2001.

(51) **Int. Cl.**

A61K 31/00 (2006.01)
A61K 31/56 (2006.01)
A61K 31/7028 (2006.01)
A61K 31/397 (2006.01)

(52) **U.S. Cl.** **514/210.02; 23/25; 23/170; 536/17.4**

(58) **Field of Classification Search** 514/170, 514/210.02, 23, 25; 424/757; 536/17.4
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,716,583 A 2/1973 Nakamura
3,781,328 A 12/1973 Witte
3,948,973 A 4/1976 Phillips
4,072,705 A 2/1978 Mieville
4,075,000 A 2/1978 Abdulla
4,144,232 A 3/1979 Koppel
4,166,907 A 9/1979 Krapcho
4,178,695 A 12/1979 Erbeia
4,179,515 A 12/1979 Mieville
4,235,896 A 11/1980 Mieville
4,250,191 A 2/1981 Edwards
4,260,743 A 4/1981 Bose
4,304,718 A 12/1981 Kamiya
4,375,475 A 3/1983 Willard
4,443,372 A 4/1984 Luo

4,479,900 A 10/1984 Luo
4,500,456 A 2/1985 Spitzer
4,534,786 A 8/1985 Luo
4,564,609 A 1/1986 Tamura
4,576,748 A 3/1986 Greenlee
4,576,749 A 3/1986 Zahler
4,576,753 A 3/1986 Kamiya
4,581,170 A 4/1986 Mueller
4,595,532 A 6/1986 Miller
4,602,003 A 7/1986 Malinow
4,602,005 A 7/1986 Malinow
4,614,614 A 9/1986 Ernest
4,616,047 A 10/1986 Lafon
4,620,867 A 11/1986 Luo
4,633,017 A 12/1986 Mueller
4,642,903 A 2/1987 Davies
4,675,399 A 6/1987 Miller
4,680,391 A 7/1987 Firestone
4,687,777 A * 8/1987 Meguro et al. 514/342
4,739,101 A 4/1988 Bourgogne
4,778,883 A 10/1988 Yoshioka
4,784,734 A 11/1988 Torii
4,794,108 A 12/1988 Kishimoto
4,800,079 A 1/1989 Boyer
4,803,266 A 2/1989 Kawashima
4,814,354 A 3/1989 Ghebre-Sellassie
4,834,846 A 5/1989 Abramson
4,871,752 A 10/1989 Ilg et al.
4,876,365 A 10/1989 Kirkup
4,879,301 A 11/1989 Umio
4,895,726 A 1/1990 Curtet
4,925,672 A 5/1990 Gremm
4,939,248 A 7/1990 Yoshioka
5,516,528 A * 5/1996 Hughes et al. 424/464
5,627,176 A * 5/1997 Kirkup et al. 514/210.02
5,656,624 A * 8/1997 Vaccaro et al. 514/210.02
5,688,787 A * 11/1997 Burnett et al. 514/210.02

(Continued)

FOREIGN PATENT DOCUMENTS

BE 884722 A 10/1980

(Continued)

OTHER PUBLICATIONS

Rosenblum et al "discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed potent orally active inhibitor of cholesterol absorption", J. Med. Chem., 1998, 41, 973-98.*

(Continued)

Primary Examiner—James O. Wilson
Assistant Examiner—Ganapathy Krishnan

(57) **ABSTRACT**

The present invention provides compositions, therapeutic combinations and methods including: (a) at least one hormone replacement therapy composition; and (b) at least one sterol absorption inhibitor which can be useful for treating vascular conditions in post-menopausal women and lowering plasma levels of sterols or 5 α -stanols.

U.S. PATENT DOCUMENTS					
			JP	63017859 A	1/1988
			JP	91068020	10/1991
5,698,527	A *	12/1997 Kim	JP	4054182 A	2/1992
5,698,548	A *	12/1997 Dugar et al.	JP	4266869 A	9/1992
5,744,467	A *	4/1998 McKittrick et al.	JP	4356195 A	12/1992
5,756,470	A *	5/1998 Yumibe et al.	JP	4356495	12/1992
5,846,966	A *	12/1998 Rosenblum et al. ...	JP	5058993 A	3/1993
5,932,562	A *	8/1999 Ostlund, Jr.	JP	5194209 A	8/1993
6,030,990	A	2/2000 Maeda et al.	JP	5239020 A	9/1993
6,166,049	A	12/2000 Smith et al.	JP	94047573	6/1994
6,440,954	B1 *	8/2002 Haber et al.	JP	95051558 B2	6/1995
6,613,757	B1 *	9/2003 Garfield et al.	WO	WO 82/01649	5/1982
2001/0028895	A1	10/2001 Bisgaier	WO	WO 87/04429	7/1987
2002/0006919	A1	1/2002 Thosar	WO	WO 88/04656	6/1988
2002/0039774	A1	4/2002 Kramer et al.	WO	WO 88/05296	7/1988
2002/0128252	A1	9/2002 Glombik et al.	WO	WO 91/03249	3/1991
2002/0128253	A1	9/2002 Glombik et al.	WO	WO 92/13837	8/1992
2002/0132855	A1	9/2002 Nelson et al.	WO	WO 93/02048	2/1993
2002/0137689	A1	9/2002 Glombik et al.	WO	WO 93/07167	4/1993
2003/0013729	A1	1/2003 Iqbal et al.	WO	WO 93/11150	6/1993
2003/0153541	A1	8/2003 Dudley et al.	WO	WO 94/00480	1/1994
			WO	WO 94/14433	7/1994
			WO	WO 94/17038	8/1994
			WO	WO 94/20535	9/1994
			WO	WO 94/26738	11/1994
			WO	WO 95/04533	2/1995
			WO	WO 95/06470	3/1995
			WO	WO 95/08532	3/1995
			WO	WO 95/18143	7/1995
			WO	WO 95/26334	10/1995
			WO	WO 95/28919	11/1995
			WO	WO 95/35277	12/1995
			WO	WO 96/00288	1/1996
			WO	WO 96/09827	4/1996
			WO	WO 96/16037	* 5/1996
			WO	WO 96/19450	6/1996
			WO	WO 96/19987	7/1996
			WO	WO 96/40255	12/1996
			WO	WO 97/16455	5/1997
			WO	WO 97/18304	5/1997
			WO	WO 97/21676	6/1997
			WO	WO 97/25042	7/1997
			WO	WO 97/28149	8/1997
			WO	WO 97/31907	9/1997
			WO	WO 97/35576	10/1997
			WO	WO 97/41098	11/1997
			WO	WO 97/46238	12/1997
			WO	WO 98/01100	1/1998
			WO	WO 98/05331	2/1998
			WO	WO 98/14179	4/1998
			WO	WO 98/31361	7/1998
			WO	WO 98/31366	7/1998
			WO	WO 98/43081	10/1998
			WO	WO 98/46215	10/1998
			WO	WO 98/47518	10/1998
			WO	WO 98/57652	12/1998
			WO	WO 99/06035	2/1999
			WO	WO 99/06046	2/1999
			WO	WO 99/08501	2/1999
			WO	WO 99/09967	3/1999
			WO	WO 99/11260	3/1999
			WO	WO 99/12534	3/1999
			WO	WO 99/04815	4/1999
			WO	WO 99/15159	4/1999
			WO	WO 99/15520	4/1999
			WO	WO 99/18072	4/1999
			WO	WO 99/20275	4/1999
			WO	WO 99/20614	4/1999
			WO	WO 99/22728	5/1999
			WO	WO 99/29300	6/1999
			WO	WO 99/38498	8/1999
			WO	WO 99/38498	8/1999

FOREIGN PATENT DOCUMENTS

CA	2253769	11/1999			
DE	2046823 A	3/1972			
DE	2521113 A	3/1976			
EP	0002151 A1	5/1979			
EP	0002151 B1	5/1979			
EP	0010299 B1	2/1984			
EP	0179559 A2	4/1986			
EP	0199630 A1	10/1986			
EP	0264231 A1	4/1988			
EP	0266896 B1	5/1988			
EP	0274873 B1	7/1988			
EP	0288973 B1	11/1988			
EP	0311366 B1	4/1989			
EP	0333268 A1	9/1989			
EP	0337549 A1	10/1989			
EP	0365364 A2	4/1990			
EP	0375527 A1	6/1990			
EP	0199630 B1	9/1990			
EP	0401705 A3	12/1990			
EP	0415487 A2	3/1991			
EP	0455042 A1	11/1991			
EP	0457514 A1	11/1991			
EP	0461548 A3	12/1991			
EP	0462667 A2	12/1991			
EP	0475148 A1	3/1992			
EP	0475755 B1	3/1992			
EP	0481671 A1	4/1992			
EP	0482498 A3	4/1992			
EP	0524595 A1	1/1993			
EP	0337549 B1	10/1995			
EP	0720599 B1	7/1996			
EP	0457514 B1	8/1996			
EP	0 753 298 A1	1/1997			
EP	0793958 A2	9/1997			
EP	0814080 A1	12/1997			
EP	0904781 A2	3/1999			
EP	1 036 563 A1	9/2000			
EP	1048295 A2	11/2000			
FR	1103113	10/1955			
FR	2779347	12/1997			
GB	861367	2/1961			
GB	902658	8/1962			
GB	1415295	11/1975			
GB	2329334 A	3/1999			
JP	136485	5/1981			
JP	028057	10/1981			
JP	180212	3/1986			
JP	121479	12/1986			

WO	WO 99/46232	9/1999
WO	WO 99/47123	9/1999
WO	WO 99/48488	9/1999
WO	WO 99/66929	12/1999
WO	WO 99/66930	12/1999
WO	WO 00/04011	1/2000
WO	WO 00/07617	2/2000
WO	WO 00/16749	3/2000
WO	WO 00/18395	4/2000
WO	WO 00/20623	4/2000
WO	WO 00/23415	4/2000
WO	WO 00/23416	4/2000
WO	WO 00/23425	4/2000
WO	WO 00/23445	4/2000
WO	WO 00/23451	4/2000
WO	WO 00/28981	5/2000
WO	WO 00/31548	6/2000
WO	WO 00/32189	6/2000
WO	WO 00/34240	6/2000
WO	WO 00/37078	6/2000
WO	WO 00/38721	7/2000
WO	WO 00/38722	7/2000
WO	WO 00/38723	7/2000
WO	WO 00/38724	7/2000
WO	WO 00/38725	7/2000
WO	WO 00/38726	7/2000
WO	WO 00/38727	7/2000
WO	WO 00/38728	7/2000
WO	WO 00/38729	7/2000
WO	WO 00/40247	7/2000
WO	WO 00/45817	8/2000
WO	WO 00/50392	8/2000
WO	WO 00/53149	9/2000
WO	WO 00/53173	9/2000
WO	WO 00/53563	9/2000
WO	WO 00/56403	9/2000
WO	WO 00/57859	10/2000
WO	WO 00/57918	10/2000
WO	WO 00/60107	10/2000
WO	WO 00/63153	10/2000
WO	WO 00/63161	10/2000
WO	WO 00/63190	10/2000
WO	WO 00/63196	10/2000
WO	WO 00/63209	10/2000
WO	WO 00/63703	10/2000
WO	WO 00/69412	11/2000
WO	WO 00/69445	11/2000
WO	WO 00/72825	12/2000
WO	WO 00/72829	12/2000
WO	WO 00/75103	12/2000
WO	WO 00/76482	12/2000
WO	WO 00/76488	12/2000
WO	WO 00/78312	12/2000
WO	WO 00/78313	12/2000
WO	WO 01/00579	1/2001
WO	WO 01/00603	1/2001
WO	WO 01/08686	2/2001
WO	WO 01/12176	2/2001
WO	WO 01/12187	2/2001
WO	WO 01/12612	2/2001
WO	WO 01/14349	3/2001
WO	WO 01/14350	3/2001
WO	WO 01/14351	3/2001
WO	WO 01/15744	3/2001
WO	WO 01/16120	3/2001
WO	WO 01/17994	3/2001
WO	WO 01/18210	3/2001
WO	WO 01/21181	3/2001
WO	WO 01/21259	3/2001
WO	WO 01/21578	3/2001
WO	WO 01/21647	3/2001

WO	WO 01/25226	4/2001
WO	WO 01/30343	5/2001
WO	WO 01/32161	5/2001
WO	WO 01/34148	5/2001
WO	WO 01/35970	5/2001
WO	WO 01/40192	6/2001
WO	WO 01/45676	6/2001
WO	WO 01/49267	7/2001
WO	WO 01/60807	8/2001
WO	WO 01/64221	9/2001
WO	WO 01/76632	10/2001
WO	WO 01/96347	12/2001
WO	WO 02/08188	1/2002
WO	WO 02/26729	4/2002
WO	WO 02/50027	6/2002
WO	WO 02/50060	6/2002
WO	WO 02/50068	6/2002
WO	WO 02/50090	6/2002
WO	WO 02/058685	8/2002
WO	WO 02/058696	8/2002
WO	WO 02/058731	8/2002
WO	WO 02/058732	8/2002
WO	WO 02/058733	8/2002
WO	WO 02/058734	8/2002
WO	WO 02/064094	8/2002
WO	WO 02/064130	8/2002
WO	WO 02/064664	8/2002
WO	WO 02/072104	9/2002
WO	WO 02/081454	10/2002
WO	WO 03/018024	3/2003
WO	WO 03/018059	3/2003
WO	WO 03/039542	5/2003
WO	WO 03/074101	9/2003
WO	WO 03/088962	10/2003

OTHER PUBLICATIONS

Michael T. Murray "Encyclopedia of Nutritional Supplements", 1996, pp. 257-258 and 317-318.*

Rosenblum et al, J. Med. Chem., 1998, 41, 973-980.*

U.S. Appl. No. 10/057,534, filed Jan. 25, 2002, Davis et al.

U.S. Appl. No. 10/057,646, filed Jan. 25, 2002, Davis et al.

U.S. Appl. No. 10/057,629, filed Jan. 25, 2002, Davis.

U.S. Appl. No. 10/154,106, filed May 22, 2002, Davis et al.

U.S. Appl. No. 10/057,323, filed Jan. 25, 2002, Davis et al.

U.S. Appl. No. 10/136,968, filed May 1, 2002, Cho et al.

U.S. Appl. No. 10/057,339, filed Jan. 25, 2002, Kosoglou et al.

U.S. Appl. No. 10/247,032, filed Jan. 25, 2002, Davis.

U.S. Appl. No. 10/056,680, filed Jan. 25, 2002, Kosoglou et al.

U.S. Appl. No. 10/247,099, filed Sep. 19, 2002, Davis et al.

U.S. Appl. No. 10/247,095, filed Sep. 19, 2002, Davis.

U.S. Appl. No. 10/246,996, filed Sep. 19, 2002, Lebeaut et al.

U.S. Appl. No. 10/247,397, filed Sep. 19, 2002, Davis et al.

U.S. Appl. No. 10/166,942, filed Jun. 11, 2002, Ghosal et al.

Vaccaro, W.D. et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar" *Bioorganic & Medicinal Chemistry Ltrs., Oxford, G.B.*, 8:313-318 (1998).

Vaccaro, W.D. et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors", *Biorganic & Medicinal Chem. Ltrs. Oxford, G.B.* 8:319-322 (1998).

H. Davis et al., "Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in Apo E^{-/-} Mice", *Arterioscler., Thromb., Vasc. Biol.*

- Simova, E., "Aldol-type addition of hydrocinnamic acid esters to benzylideneaniline", *Chemical Abstracts No. 15*, 86 (Apr. 11, 1997).
- Otto et al., Stereochemistry of dehydration and halogenation of α R* and α S* isomeric 3-(α -hydroxybenzyl)-1,4-diphenyl-2-azetidiones, *Chemical Abstracts No. 19*, 99 (Nov. 7, 1983).
- T. Durst et al., "Metallation of N-Substituted β -Lactams. A Method of the Introduction of 3-substituents into β -Lactams" *Canadian Journal of Chemistry*, 50:3196-3201 (1971).
- Nobuki, O. et al., "Stereoselective syntheses of β -lactam derivatives by ultrasound promoted Reformatskii reaction" *Chemical Abstracts No. 106*, 17 (Apr. 27, 1987).
- M. Hoekman, et al., "Synthesis of Homologues of 4,5-Dihydroxy-and 4-Hydroxy-5-oxohexanoic Acid γ -Lactones", *J. Agric. Food Chem.*, 30:920-924 (1982).
- H. Otto et al. "Darstellung und Stereochemie von 3-(α -Hydroxybenzyl)-1,4-diphenyl-2-azetidinonen", *Liebigs Ann. Chem.* 1152-1161 (1983).
- G. George et al. "3-(1'-Hydroxyethyl)-2-Azetidinones From 3-Hydroxybutyrates and N-Arylaldimines" *Tetrahedron Letters*, 26:3903-3906 (1985).
- Hart et al. "An Enantioselective Approach to Carbapenem Antibodies: Formal Synthesis of (+)-Thienamycin", *26 Tetrahedron Letters*, 45:5493-5496 (1985).
- Panfil, I. et al. "Synthesis of β -Lactams from α , β -Unsaturated Sugar δ -Lactones" *24 Heterocycles* 6:1609-1617 (1986).
- D. Roger Illingworth, "An Overview of Lipid-Lower Drugs" *Drugs* 36:63-71 (1988).
- Joseph L. Witztum, M.D., "Current Approaches to Drug Therapy for the Hypercholesterolemic Patient" *Circulation* 80:1101-1114 (1989).
- B. Ram et al. "Potential Hypolipidemic agents: Part V", *29B Indian J. Chem.* 1134-37 (1990).
- Schnitzer-Polokoff, R. et al., "Effects of Acyl-CoA:Cholesterol O-Acyltransferase Inhibition on Cholesterol Absorption and Plasma Lipoprotein Composition in Hamsters" *Comp. Biochem. Physiol.* 99A:665-670 (1991).
- Horie, M. et al., "Hypolipidemic effects of NB-598 in dogs" *Atherosclerosis* 88:183-192 (1991).
- Baxter, A., "Squalenstatin 1, a Potent Inhibitor of Squalene Synthase, Which Lowers Serum Cholesterol in Vivo", *The Journal of Biological Chemistry* 267:11705-11708 (1992).
- Summary Factfile, "Anti-Atherosclerotic Agents" *Current Drugs Ltd.* (1992).
- Harwood H. James, "Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β -tigogenin cellobioside (CP-88818; tiqueside) 1" *Journal of Lipid Research* 34:377-395 (1993).
- Salisbury, B. et al., "Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461" *Atherosclerosis* 115:45-63 (1995).
- Clader, J. W. et al., "Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups in Vitro and in Vivo Activity" *Journal of Medicinal Chemistry* 38:1600-1607 (1995).
- Sybertz, E., "Sch 48461, a novel inhibitor of cholesterol absorption" *Atherosclerosis* pp. 311-315 (1995).
- Vaccaro, W, et al., "2-Azetidinone Cholesterol Absorption Inhibitors: Improved Potency by Substitution of the C-4
- G. Wu et al, A Novel One-Step Diastereo- and enantioselective formation of trans-azetidiones and its application to the total synthesis of cholesterol absorption inhibitors A.C.S. (Apr. 21, 1999).
- B. Staels, "New Roles for PPARs in Cholesterol Homeostasis", *Trends in Pharmacological Sciences*, 22:9 p. 444 (Sep. 2001).
- Abbott et al, "Tricor® Capsules, Micronized", *Physicians Desk Reference*, Jan. 8, 2001.
- M. Feher et al., 1991, *Lipids and Lipid Disorders*, p. 1-87 (1991).
- M. Ricote et al., "New Roles for PPARs in Cholesterol Homeostasis", *Trends in Pharmacological Science*, vol. 22, No. 9 441-443 (2001).
- C. Dujovne et al, "Reduction of LDL Cholesterol in Patients with Primary Hypercholesterolemia by SCH 48461: Results of a multicenter Dose-Ranging Study", *J. Clin., Pharm.* 41:1 70-78 (Jan. 2001).
- W. Oppolzer et al., "Asymmetric Diels-Alder Reactions, Facile Preparation and Structure of Sulfonamido-Isobornyl Acrylates", *Tetrahedron Letters No. 51*, 25:5885-5888 (1984).
- M. Davidson et al., "Colesevelam Hydrochloride: a non-absorbed, polymeric cholesterol lowering agent", *Expert Opinion Investigating Drugs*, 11:2663-71, (Nov. 2000).
- M. Davidson et al., "Colesevelam hydrochloride (cholestagel): a new, potent bileacid sequestrant associated with a low incidence of gastrointestinal effects", *159 Arch. Intern. Med.* 16 1893-900 (Sep. 1999).
- I. Wester, "Cholesterol—Lowering effect of plant sterols", *Euro. J.Lipid, Sci. Tech.* 37-44 (2000).
- A. Andersson et al., "Cholesterol—lowering effects of a stanol ester-containing low fat margarine used in conjunction with a strict lipid-lowering diet", *1 European Heart. J. Supplements* S80-S90 (1999).
- H. Gylling et al, Reduction of Serum Cholesterol on Postmenopausal Women with Previous Myocardial Infarction and Cholesterol Malabsorption induced by Dietary Sitostanol Ester Margarine, *96 Circulation* 12 4226-4231 (Dec. 16, 1997).
- T. Miettinen et al, "Reduction of Serum Cholesterol with Sitostanol-Ester Margarine in a Mildly Hypercholesterolemic Population", *New England Journal of Med.* 333 1308-1312 (Nov. 16, 1995).
- T. Bocan et al., "The ACAT Inhibitor Avasimibe Reduces Macrophages and Matrix Metalloproteinase Expression in Atherosclerotic Lesions of Hypercholesterolemic Rabbits", *Arterioscler Thromb Vasc. Biol.* 70-79 (Jan. 2000).
- M. Van Heek et al., "In Vivo Metabolism—Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH 58235, in the Rat and Rhesus Monkey through the identification of the active metabolites of SCH48461," *283 J. Pharma and Experimental Therapeutics* 1 157-163 (1997).
- H. Davis et al., "The Cholesterol Absorption Inhibitor Ezetimibe Inhibits the Development of Atherosclerosis in apo E knockout (-/-) mice fed low fat and western diets," *151 Atherosclerosis* 1133 (Jul. 2000).
- L. Nguyen et al., "Unexpected Failure of Bile Acid Malabsorption to Stimulate Cholesterol Synthesis in Sitosterolemia with Xanthomatosis", *10 Atherosclerosis* 2, 289-297 (1990).
- L. Nguyen et al., "Regulation of Cholesterol Biosynthesis in Sitosterolemia: effects of lovastatin, Cholestyramine, and Diet", *Journal of Lipid Research* 33:1041-1048 (1992).

- cholestyramine and Lovastatin on Plasma Sterol Levels in a Homozygous Girl and Her Heterozygous Father," *45 Metabolism* 6 673-679 (Jun. 1996).
- M. Huettinger et al., "Hypolipidemic Activity of HOE-402 is mediated by Stimulation of the LDL Receptor Pathway", *13 Arteriosclerosis and Thrombosis* 7 1005-1012 (Jul. 1993).
- J. Best et al., "Diabetic Dyslipidaemia", *59 Drugs* 5 1101-1111 (May 2000).
- P. Chong, et al, "Current, New and Future Treatment in Dyslipidaemia and Atherosclerosis", *60 Drugs* 1 55-93 (Jul. 2000).
- M. Brown et al, "A Receptor—Mediated Pathway for Cholesterol Homeostasis", *232 Science* 34-47 (Apr. 4, 1986).
- L. Lipka et al., "Reduction of LDL-Cholesterol and Elevation of HDL-Cholesterol in Subjects with Primary Hypercholesterolemia by SCH 58235: Pooled Analysis of Two Phase II Studies", *JACC* 257A (Feb. 2000).
- Medical Economics, Co., Inc., *Physician's Desk Reference*, 207-208, 2054 (55th Ed. 2001).
- K. Fassbender et al., "Simvastatin Strongly Reduces Levels of Alzheimer's Disease β -Amyloid Peptides A β 42 and A β 40 in vitro and in vivo", *PNAs Early Edition*, www.phas.org/cgi/doi/10.1073/phas.081620098 (2001).
- Andrx Announces Results of Alzheimer's Disease Clinical Study, *Andrx Corporate Release* (Apr. 11, 2001).
- Andrx (ADRX): Pos Phase II Results Using Avicor in Alzheimer's: Str Buy; \$130, *US Bancorp Piper*, Apr. 12, 2001.
- Statins May Protect Against Alzheimer's Disease; much research needed, *Geriatrics* Feb. 2001.
- Dementia and Statins, *The Lancet* Mar. 17, 2001.
- Research & Development: Andrx Says Cholesterol Drug May Treat Alzheimers, *Reuters* Apr. 11, 2001.
- Cholesterol Drugs Ease Alzheimer's Damage; www.usatoday.com Apr. 10, 2001.
- Lovastatin XL of Use in Alzheimer's? News Edge (May 2, 2001).
- L. Refolo et al, Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model, *Neurobiology of Disease* 321-331 (2000).
- D. Kang et al., "Modulation of Amyloid β -protein Clearance and Alzheimer's Disease Susceptibility by the LDL Receptor—Related Protein Pathway", *Journal of Clinical Investigation* 106:9, 1159-1166 (Nov. 2000).
- Y.A. Kesaniemi, "Intestinal Cholesterol Absorption Efficiency in Man is Related to Apoprotein E Phenotype", *J. Clin. Invest.* 80(2) 578-81 (Aug. 1987).
- J. Busciglio et al., "Generation of β -amyloid in the secretory pathway in neuronal and nonneuronal cells", *90 Proc. Nat'l Acad. Sci, USA*, 2092-2096 *Neurobiology* (Mar. 1993).
- L. Farrer et al., "Assessment of Genetic Risk for Alzheimer's Disease Among first Degree Relatives", *Annals of Neurology* 25:5, 485-493 (May 1989).
- A. Goate et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", *349 Nature No. 6311*, 704-706 (Feb. 21, 1991).
- D. Mann et al., "The Pattern of Acquisition of Plaques and Tangle in the Brains of Patients Under 50 years of Age with Down's Syndrome", *89 J. Neuro. Sci.*, 169-179 (Feb. 1989).
- G. McKhann et al., "Clinical Diagnosis of Alzheimer's Disease", *34 Neurology No. 7*, 939-944 (Jul. 1984).
- C. Van Duijn, et al., "Familial Aggregation of Alzheimer's Disease and Related Disorders: A collaborative Re-Analysis of Case-Control Studies", *20 Int'l J. Epidemiology No. 2 (Suppl. 2)*, 513-520 (1991).
- T Nagahara et al., "Dibasic (Amidinoaryl) Propanoic Acid Derivatives as Novel Blood Coagulation Factor Xa Inhibitors", *J. Med. Chem* 37:1200-1207 (1994).
- Mellot et al., "Acceleration of Recombinant Tissue-Type Plasminogen Activator Induced Reperfusion and Prevention of Reocclusion by Recombinant Antistasin, a selective factor Xa Inhibitor, in a Canine Model of Femoral Arterial Thrombosis", *Circulation Research*, 70:1152-1160 (1992).
- Sitko et al., "Conjunctive Enhancement of Enzymatic Thrombolysis and Prevention of Thrombotic Reocclusion With the Selective Factor Xa Inhibitor, Tick Anticoagulant Peptide", *Circulation*, 85:805-815 (1992).
- Seymour et al., 1994, *Biochemistry*, 33:3949-3959.
- Markwardt, 1994, *Thrombosis and Hemostasis*, 72:477-479.
- Mendall et al., "C-Reactive Protein and its relation to cardiovascular risk factor: A population based cross sectional study", *BMJ*; 312:1061-1065 (Apr. 27, 1996).
- Ridker P. et al., "Prospective Studies of C-Reactive Protein as a risk factor for cardiovascular disease", *46 J. Investig. Med.*; 8:391-395 (1998).
- L. Gruber, 2000, "Inflammatory Markers in Acute Coronary Syndromes: C-reactive protein (CRP) and Chlamydia", *American Heart Association Scientific Sessions*.
- Waters, D. et al., "A Controlled Clinical Trial to Assess the Effect of a Calcium Channel Blocker on the Progression of Coronary Atherosclerosis", *Circulation*; 82:1940-1953 (1990).
- Fleckenstein, 1985, *Cir. Res.* vol. 52 (Suppl. 1) 3-16.
- Fleckenstein, 1983, "Experimental Facts and Therapeutic Prospects", *John Wiley, New York*, pp. 286-313.
- McCall, D., 1985, *Curr. Pract. Cardiol.* vol. 10, 1-11.
- Remington 1995, *The Science and Practice of Pharmacy*, (19th Ed. 1995) p. 963.
- M. Chistie et al., "Early—Onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695", *276 J. Biol. Chem. No. 24*; 21562-70 (Jun. 15, 2001).
- C. Janus et al., "A β Peptide Immunization Reduces Behavioral impairment and Plaques in a Model of Alzheimer's Disease", *408 Nature* 21/28; 979-982 (Dec. 2000).
- Manual of Laboratory Operations, Lipid Research Clinics Program Report, Washington, D.C., *U.S. Dept. of Health, Education and Welfare Publication*; 1:75-628 (1974).
- Steiner, PM et al., Standardization of Micromethods for Plasma Cholesterol, Triglyceride and HDL-Cholesterol with the Lipid Clinic's Methodology [abstract], *J. Clin. Chem. Clin. Biochem*; 19:850 (1981).
- Steele WG, et al., Enzymatic Determinations of Cholesterol in High Density Lipoprotein Fractions Prepared by Precipitation Technique, *22 Clin. Chem.*; 1:98-101 (1976).
- Salen et al., "Increased Sitosterol Absorption, Decreased Removal and Expanded Body Pools Compensate for Reduced Cholesterol Syntheses in Sitosterolemia with Xanthomatosis", *J. Lipid Res.*; 30:1319-1330 (1989).
- Lutjohann et al., "Sterol Absorption and Sterol Balance in Phytosterolemia Evaluated by Deuterium-Labeled Sterols: Effect of Sitostanol Treatment", *J. Lipid Res.*; 36:8; 1763-1773 (1995).
- Zhang et al., "Calpain Inhibitor 1 Increases B- Amyloid Precursor Protein and Inhibits the Degradation of Secreted β -Amyloid"

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.